Cerenome is trading 7.01% higher at $1.68, with no confirmed company-specific catalyst for the gain. - Shares have recovered from the October 26 close of $1.57. - On October 27, the company announced it will present interim data from its ReSPECT-LMM multidose study at the Society for Neuro-Oncology meeting in November. This is a future presentation, not results released today. - The broader market is higher, but available figures are mixed and do not establish that market sentiment drove Cerenome’s move.